Skip to content
TPD and Neo Europe (3)

Weaponizing truly individualized therapies

The 4th Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting. Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode. At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss:

  • Reducing the discordance between various neoantigen prediction methods
  • Maximising the immune response to neoantigens
  • Shortening the needle-to-needle time of personalised cancer immunotherapy
  • Navigating the evolving regulatory landscape to faster approval

Join the leaders from BioNTechGenentechGenoceaGritstone OncologyAgenusZiopharmVaccibody and many more to spur on more efficacious personalised cancer vaccines and cell therapies.